Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe: lessons for the accelerated approval pathway by Mahnum Shahzad, Huseyin Naci, Katharine M. Esselen, Joseph A. Dottino, Anita K. Wagner

Connect to this object online.

Avoidable costs of stenting for aortic coarctation in the United Kingdom: an economic model by Maximilian Salcher, Alistair Mcguire, Vivek Muthurangu, Marcus Kelm, Titus Kuehne, Huseyin Naci, CARDIOPROOF

Connect to this object online.

Efficacy and safety of interim oncology treatments introduced for solid cancers during the COVID-19 pandemic in England: a retrospective evidence-based analysisResearch in context by Mark P. Lythgoe, Alica-Joana Emhardt, Huseyin Naci, Jonathan Krell, Richard Sullivan, Ajay Aggarwal

Connect to this object online.

Cancer drug indication approvals in China and the United States: a comparison of approval times and clinical benefit, 2001-2020Research in context by Yuxuan Wei, Yichen Zhang, Ziyue Xu, Guoan Wang, Yue Zhou, Huangqianyu Li, Luwen Shi, Huseyin Naci, Anita K. Wagner, Xiaodong Guan

Connect to this object online.

Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysisResearch in context by Adriana M. Ivama-Brummell, Fernanda L. Marciniuk, Anita K. Wagner, Claudia G.S. Osorio-, Sabine Vogler, Elias Mossialos, Carla L. Tavares-, Huseyin Naci

Connect to this object online.